Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Patents and regulatory exclusi...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019

Show other versions (1)
Bibliographic Details
Main Authors: Anders Olsen, Reed F. Beall, Ryan P. Knox, Sean S. Tu, Aaron S. Kesselheim, William B. Feldman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-11-01
Series:PLoS Medicine
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653475/?tool=EBI
  • Holdings
  • Description
  • Other Versions (1)
  • Similar Items
  • Staff View

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653475/?tool=EBI

Similar Items

  • Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
    by: Anders Olsen, et al.
    Published: (2023-11-01)
  • Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997
    by: Babak Sahragardjoonegani, et al.
    Published: (2021-12-01)
  • Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
    by: Aaron S Kesselheim, et al.
    Published: (2022-12-01)
  • Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
    by: Bishal Gyawali, et al.
    Published: (2020-04-01)
  • THPdb: Database of FDA-approved peptide and protein therapeutics.
    by: Salman Sadullah Usmani, et al.
    Published: (2017-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs